<DOC>
	<DOCNO>NCT00601861</DOCNO>
	<brief_summary>The trial conduct Europe . This trial aim comparison pathology lymph node effect recombinant interleukin-21 patient stage III melanoma</brief_summary>
	<brief_title>Effect rIL-21 Metastases Lymph Nodes Melanoma Skin Cancer</brief_title>
	<detailed_description>The decision discontinue NN028-1801 trial due safety concern . The trial terminate result strategic decision sponsor company .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Stage III melanoma ECOG performance status 01 Signs stage IV melanoma Safety variable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>